Analysts Set Avanos Medical Inc (NYSE:AVNS) Price Target at $51.25

Share on StockTwits

Shares of Avanos Medical Inc (NYSE:AVNS) have received a consensus rating of “Hold” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating and four have issued a buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $51.25.

A number of research firms recently issued reports on AVNS. ValuEngine raised shares of Avanos Medical from a “hold” rating to a “buy” rating in a report on Tuesday, July 2nd. Zacks Investment Research downgraded shares of Avanos Medical from a “hold” rating to a “sell” rating in a report on Monday, May 6th. Raymond James lowered their price target on shares of Avanos Medical from $57.00 to $48.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Morgan Stanley set a $47.00 price target on shares of Avanos Medical and gave the company a “sell” rating in a report on Wednesday, May 8th. Finally, Stifel Nicolaus set a $45.00 price target on shares of Avanos Medical and gave the company a “buy” rating in a report on Wednesday, August 7th.

Shares of AVNS traded up $0.42 on Friday, reaching $36.55. The company’s stock had a trading volume of 226,200 shares, compared to its average volume of 340,787. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.06 and a quick ratio of 2.35. The stock has a market capitalization of $1.72 billion, a P/E ratio of 44.57 and a beta of 1.46. The stock’s 50 day simple moving average is $40.87 and its two-hundred day simple moving average is $43.00. Avanos Medical has a 12-month low of $35.21 and a 12-month high of $72.96.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.25 by $0.03. The company had revenue of $172.20 million for the quarter, compared to the consensus estimate of $172.02 million. Avanos Medical had a negative net margin of 3.92% and a positive return on equity of 4.18%. The firm’s revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.20 earnings per share. Analysts expect that Avanos Medical will post 1.2 earnings per share for the current year.

In other news, CEO Joseph Fralin Woody purchased 3,500 shares of the stock in a transaction on Thursday, May 30th. The shares were acquired at an average price of $39.95 per share, with a total value of $139,825.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 1.57% of the stock is owned by insiders.

A number of large investors have recently modified their holdings of AVNS. Norges Bank bought a new stake in shares of Avanos Medical during the fourth quarter valued at approximately $33,253,000. RGM Capital LLC raised its position in shares of Avanos Medical by 1,659.3% during the second quarter. RGM Capital LLC now owns 751,523 shares of the company’s stock valued at $32,774,000 after buying an additional 708,806 shares during the last quarter. Victory Capital Management Inc. raised its position in shares of Avanos Medical by 31.3% during the first quarter. Victory Capital Management Inc. now owns 2,196,725 shares of the company’s stock valued at $93,756,000 after buying an additional 523,550 shares during the last quarter. Rice Hall James & Associates LLC bought a new stake in shares of Avanos Medical during the first quarter valued at approximately $16,219,000. Finally, Champlain Investment Partners LLC raised its position in shares of Avanos Medical by 14.5% during the first quarter. Champlain Investment Partners LLC now owns 2,401,987 shares of the company’s stock valued at $102,517,000 after buying an additional 304,015 shares during the last quarter. 92.24% of the stock is currently owned by institutional investors and hedge funds.

About Avanos Medical

Avanos Medical, Inc operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes.

Further Reading: How mutual funds make money

Analyst Recommendations for Avanos Medical (NYSE:AVNS)

Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.